Track topics on Twitter Track topics that are important to you
Market: Euronext ParisISIN code Mnemo: CH0308403085 GNROWeb site: www.geneuro.com Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of ...
Geneuro's GNBAC1 was given orphan drug status by the FDA as a treatment for patients with chronic inflammatory demyelinating -More-
Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO) (Paris: GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis and Type 1 d...
GeNeuro and French independent pharma company Servier today announced positive results at 12 months from…
The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro dev...
GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been in our genome since an...
GNbAC1 targets pHERV-W env, which is found in half of CIDP patients Forthcoming discussions expected with the FDA for the design of a proof-of-concept Phase 2 clinical study Regulatory News: GeNeu...
GeNeuro is a Swiss-based company created by Eclosion in 2006 as a spin-off of bioMÃ©rieux and co-funded by Eclosion and the Institut MÃ©rieux. GeNeuro is developing first-in-c...
We have published hundreds of GeNeuro SA news stories on BioPortfolio along with dozens of GeNeuro SA Clinical Trials and PubMed Articles about GeNeuro SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GeNeuro SA Companies in our database. You can also find out about relevant GeNeuro SA Drugs and Medications on this site too.